Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Monday . The stock had previously closed at $15.06, but opened at $15.91. Ascentage Pharma Group International shares last traded at $15.98, with a volume of 6,704 shares.

Analysts Set New Price Targets

Several brokerages have commented on AAPG. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Finally, BTIG Research reissued a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Two research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The stock’s 50 day moving average is $17.77 and its two-hundred day moving average is $20.14.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million during the quarter. Sell-side analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.